Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 7/17/11 → 4/30/12 |
Funding
- Talecris Biotherapeutics: $5,985.00
A Phase Two, Randomized, Open-Label (with Blinded Plasminogen Activator and Placebo Control Group Study to Evaluate the Effects of Different Intra-Thrombus Infusion Regimens of Plasmin (Human) Compared to Plasminogen Activator and Placebo
- Saha, Sibu (PI)